JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas

  • 0Department of Cerebrovascular Disease and Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Annals of Clinical and Translational Neurology +

|

November 18, 2024

|

November 18, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new nomogram model accurately predicts glioma grade and IDH mutation status using imaging and molecular features. This non-invasive tool aids clinical decisions for better patient management in diffuse glioma.

Area Of Science

  • Neuro-oncology
  • Radiology
  • Molecular Diagnostics

Background

  • Glioma grading and isocitrate dehydrogenase (IDH) mutation status are critical for patient prognosis and treatment.
  • Accurate non-invasive methods are needed to differentiate glioma grades and determine IDH mutation status.

Purpose Of The Study

  • To develop and validate a predictive model for glioma grading and IDH mutation status.
  • To assess the efficacy of imaging features and magnetic resonance spectroscopy (MRS) in differentiating glioma subtypes.

Main Methods

  • Retrospective analysis of 383 adult diffuse glioma patients across two institutions.
  • Construction of a nomogram model using stepwise regression based on clinical and radiographic features.
  • Evaluation of Hyper fluid-attenuated inversion recovery (FLAIR) rim sign, T2-FLAIR mismatch sign, and MRS indicators (Cho/Cr ratio).

Main Results

  • The T2-FLAIR mismatch sign showed better clinical efficacy than the Hyper FLAIR rim sign for predicting glioma grade and IDH mutation status.
  • Preoperative MRS indicators, particularly the Cho/Cr ratio, demonstrated excellent performance.
  • The developed nomogram exhibited excellent predictive capabilities for glioma grading and IDH mutation status.

Conclusions

  • A combined imaging and molecular predictive model offers a reliable non-invasive tool for glioma grading and IDH mutation status determination.
  • This model can aid clinical decision-making and improve patient management strategies for diffuse gliomas.